CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.16BUSDvs all stocks (USD)
Revenue (TTM)
119.01MUSDvs all stocks (USD)
Profit Margin
-61.31%vs Medical Devices peers
52-Week Change
8.34%vs all stocks
Market Capitalization
1.16BUSDvs all stocks (USD)
Enterprise Value
793.75MUSDvs all stocks (USD)
Forward P/E
-9.25xvs Medical Devices peers
Price to Sales (TTM)
9.75xvs Medical Devices peers
Price to Book (MRQ)
3.77xvs Medical Devices peers
Enterprise to Revenue
6.67xvs Medical Devices peers
Enterprise to EBITDA
-9.82xvs Medical Devices peers
Gross Margin
59.04%vs Medical Devices peers
Profit Margin
-61.31%vs Medical Devices peers
Operating Margin
-79.90%vs Medical Devices peers
Return on Assets (TTM)
-16.67%vs Medical Devices peers
Return on Equity (TTM)
-26.16%vs Medical Devices peers
Revenue (TTM)
119.01MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.69USDUpdated Sep 27, 2026Quarterly Revenue Growth
37.80%vs Medical Devices peers
Gross Profit (TTM)
69.40MUSDvs all stocks (USD)
EBITDA (TTM)
-80.80MUSDvs all stocks (USD)
Net Income (TTM)
-72.97MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
37.76%vs Medical Devices peers
Operating Cash Flow (TTM)
-55.81MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-40.29MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
100.25MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
44.71MUSDFY2025 · Dec 31, 2025Gross Profit
55.54MUSDFY2025 · Dec 31, 2025Operating Income
-71.68MUSDvs all stocks (USD)
Pre-tax Income
-73.20MUSDFY2025 · Dec 31, 2025Net Income
-73.20MUSDFY2025 · Dec 31, 2025EBIT
-71.68MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-56.36MUSDFY2025 · Dec 31, 2025Research & Development
34.79MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
92.43MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.93MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.81USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.81USDFY2025 · Dec 31, 2025Basic Shares Outstanding
40.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
40.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-73.20MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-66.54MUSDFY2025 · Dec 31, 2025Free Cash Flow
-71.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
31.68MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-73.20MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.88MUSDFY2025 · Dec 31, 2025Stock-based Compensation
16.38MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.99MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-5.16MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.10MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.54MUSDFY2025 · Dec 31, 2025Capital Expenditures
-5.30MUSDFY2025 · Dec 31, 2025Purchase of Investments
-327.51MUSDFY2025 · Dec 31, 2025Sale of Investments
170.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-162.81MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
210.12MUSDFY2025 · Dec 31, 2025Shares Outstanding
44.98MSharesUpdated Sep 27, 2026Float Shares
31.16MSharesUpdated Sep 27, 2026Shares Short
10.62MSharesUpdated Sep 27, 2026Short Ratio
9.85daysvs all stocks
Short % of Shares Outstanding
23.71%vs all stocks
% Held by Insiders
0.82%vs all stocks
% Held by Institutions
95.84%vs all stocks
Total Cash (MRQ)
180.49MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.01USDUpdated Sep 27, 2026Total Debt (MRQ)
6.51MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0254xvs Medical Devices peers
Current Ratio (MRQ)
8.88xvs Medical Devices peers
Book Value per Share (MRQ)
5.70USDUpdated Sep 27, 2026Total Assets
328.74MUSDvs all stocks (USD)
Total Current Assets
267.90MUSDFY2025 · Dec 31, 2025Total Liabilities
41.13MUSDFY2025 · Dec 31, 2025Total Non-current Assets
60.84MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
10.21MUSDFY2025 · Dec 31, 2025Total Current Liabilities
30.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
31.58MUSDFY2025 · Dec 31, 2025Other Short-term Investments
187.55MUSDFY2025 · Dec 31, 2025Accounts Receivable
17.12MUSDFY2025 · Dec 31, 2025Inventory
21.72MUSDFY2025 · Dec 31, 2025Accounts Payable
5.00MUSDFY2025 · Dec 31, 2025Short-term Debt
1.94MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.56MUSDFY2025 · Dec 31, 2025Other Current Liabilities
328.00KUSDFY2025 · Dec 31, 2025Long-term Debt
5.37MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.55MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-369.94MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
287.61MUSDvs all stocks (USD)
52-Week Low
8.80USDUpdated Sep 27, 202652-Week High
32.71USDUpdated Sep 27, 202652-Week Change
8.34%vs all stocks
50-Day MA
18.12USDUpdated Sep 27, 2026200-Day MA
16.07USDUpdated Sep 27, 2026Avg 10-Day Volume
2.03MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.35MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.60USDUpdated Sep 27, 2026Other Income / Expense
-12.45MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.59Profit Margin: -0.61
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Tianjin Ringpu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sanofi Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Glass House Brands Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Chongqing Taiji Industry Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Avanos Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Innovita Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Geron Corporation
2 interpretationsPartial Recovery After Sharp DeclineHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Microvision Inc.
2 interpretationsPartial Recovery After Sharp DeclineHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
BTQ Technologies Corp.
2 interpretationsPartial Recovery After Sharp DeclineHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC